EVERETT, Wash. -- (BUSINESS WIRE) -- SNBL USA, the experts in primate research, is pleased to announce the appointment of Steve Glaza as the director of safety assessment. As the newest member of the SNBL USA leadership team, Glaza is responsible for all facets of the safety assessment department. He will manage day-to-day operations of the department to ensure continued operational and scientific excellence. In addition, Glaza will work with the executive management team in formulating and directing current and long-range plans, objectives and policies to support sponsors with the highest level of compliance and efficiency.
Prior to joining SNBL USA, Glaza was with Covance Laboratories for more than 30 years. He started in Madison, Wisc., as a group leader in the toxicology department and quickly moved up the ranks to manager/study director then associate director of formulations followed by associate director of toxicology/safety assessment. He became the site manager for the dedicated client facility before moving to Chandler, Ariz., to take the position of associate director and site scientific lead of safety assessment.
“We are very excited to have Steve join SNBL USA,” said Dr. Thomas Beck, SNBL USA president and COO. “His wealth of experience in the CRO industry makes him an ideal team leader to successfully synchronize industry regulations and compliance with client expectations."
Contact SNBL USA for any questions regarding safety assessment services. Reach the client services team at 425.322.1950 or email@example.com.
About SNBL USA, Ltd.
Headquartered in Everett, Wash., SNBL USA, Ltd. offers a unique range of safety assessment services to fulfill its commitment to help free patients from suffering. Managed and operated by a team world renowned for its wide-ranging nonhuman primate (NHP) experience and expertise, SNBL offers programs ranging from regulatory toxicology to customized study designs. SNBL’s specialized capabilities include safety assessment of biologics, reproductive toxicology, cardiovascular, respiratory and CNS pharmacology, immunotoxicology and carcinogenicity.